A new rating scale for Alzheimer's disease

The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects

Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117 · see citing works

Pathological verification of ischemic score in differentiation of dementias

Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., & Peck, A. (1980) · Annals of Neurology · doi:10.1002/ana.410070516 · Cited by 1,273 · see citing works

A New Scale for Clinical Assessment in Geriatric Populations: Sandoz Clinical Assessment – Geriatric (SCAG)*

Shader, R. I., Harmatz, J. S., & Salzman, C. (1974) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1974.tb01521.x · Cited by 307 · see citing works

Effects of Naloxone in Senile Dementia: A Double-Blind Trial

Reisberg, ‌., Ferris, S. H., Anand, R., Mir, P., Geibel, V., de Leon, M. J., & Roberts, E. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303243081213 · Cited by 151 · see citing works

RELIABILITY AND VALIDITY OF A SCALE FOR ASSESSING THE FUNCTIONING OF GERIATRIC PATIENTS

Plutchik, R., Conte, H. R., Lieberman, M., Bakur, M., Grossman, J., & Lehrman, N. S. (1970) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1970.tb01335.x · Cited by 114 · see citing works

ALZHEIMERʼS DISEASE

Sim, M., & Sussman, I. (1962) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196212000-00002 · Cited by 113 · see citing works

Apomorphine and Other Dopaminomimetics: Basic Pharmacology, Vol. I

Davis, G. C. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.6.838 · Cited by 109 · see citing works

A Brief Psychogeriatric Assessment Schedule

Pattie, A. H., & Gilleard, C. J. (1975) · The British Journal of Psychiatry · doi:10.1192/bjp.127.5.489 · Cited by 101 · see citing works

Clinical Value of the London Psychogeriatric Rating Scale

Hersch, E. L., Kral, V. A., & Palmer, R. (1978) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1978.tb03682.x · Cited by 100 · see citing works

Enhancement of Memory by Physostigmine

(1979) · New England Journal of Medicine · doi:10.1056/nejm197910253011721 · Cited by 99 · see citing works

Choline chloride fails to improve cognition in Alzheimer's disease

Thal, L. J., Rosen, W. G., Sharpless, N. S., & Crystal, H. (1981) · Neurobiology of Aging · doi:10.1016/0197-4580(81)90022-1 · Cited by 66 · see citing works

Physical and Mental Impairment-of-Function Evaluation in the Aged: The PAMIE Scale

Gurel, L., Linn, M. W., & Linn, B. S. (1972) · Journal of Gerontology · doi:10.1093/geronj/27.1.83 · Cited by 61 · see citing works

Some Aspects of Language in Various Forms of Senile Dementia (Comparisons with Language in Childhood)

de Ajuriaguerra, J., & Tissot, R. (1975) · Elsevier eBooks · doi:10.1016/b978-0-12-443701-2.50030-5 · Cited by 49 · see citing works

INCIDENCE OF ALZHEIMER'S DISEASE IN A LARGE MENTAL HOSPITAL

NEUMANN, M. A. (1953) · A M A Archives of Neurology & Psychiatry · doi:10.1001/archneurpsyc.1953.02320290067008 · Cited by 46 · see citing works

The Stockton Geriatric Rating Scale: A Shortened Version with British Normative Data

Gilleard, C. J., & Pattie, A. H. (1977) · The British Journal of Psychiatry · doi:10.1192/bjp.131.1.90 · Cited by 40 · see citing works

Rating scales for geriatric psychopharmacology--a review.

Salzman, C., Kochansky, G. E., & Shader, R. I. (1972) · PubMed · Cited by 32 · see citing works

Dihydroergotoxine: 6‐Mg versus 3‐Mg Dosage in the Treatment of Senile Dementia. Preliminary Report*

Yesavage, J. A., Hollister, L. E., & Burian, E. (1979) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1979.tb03345.x · Cited by 21 · see citing works

Research subject recruitment for gerontological studies of pharmacological agents

Levy, M. I., Mohs, R. C., Rosen, W. G., & Davis, K. L. (1982) · Neurobiology of Aging · doi:10.1016/0197-4580(82)90064-1 · Cited by 20 · see citing works

The Impairment Index as a Symptom-Independent Parameter of Drug Efficacy in Geriatric Psychopharmacology

Branconnier, R. J., & Cole, J. O. (1978) · Journal of Gerontology · doi:10.1093/geronj/33.2.217 · Cited by 15 · see citing works

Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review

Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589 · see citing works

Dementia prevention, intervention, and care

Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072 · see citing works

Current concepts in mild cognitive impairment

Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781 · see citing works

Alzheimer's Disease Neuroimaging Initiative (ADNI)

Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572 · see citing works

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity

Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519 · see citing works

A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease

Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · see citing works

The cholinergic hypothesis of Alzheimer’s disease: A review of progress

Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · see citing works

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · see citing works

Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial

Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178 · see citing works

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · see citing works

Cholinesterase inhibitors for Alzheimer's disease

Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906 · see citing works

The Hawthorne Effect: a randomised, controlled trial

McCarney, R., Warner, J. P., Iliffe, S., van Haselen, R. A., Griffin, M., & Fisher, P. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-30 · Cited by 1,730 · see citing works

Effect of Physical Activity on Cognitive Function in Older Adults at Risk for Alzheimer Disease: A Randomized Trial

Lautenschlager, N. T., Cox, K. L., Flicker, L., Foster, J. K., van Bockxmeer, F. M., Xiao, J., Greenop, K. R., & Almeida, O. P. (2008) · JAMA · doi:10.1001/jama.300.9.1027 · Cited by 1,637 · see citing works

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618 · see citing works

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery

Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573 · see citing works

Alzheimer’s Disease Neuroimaging Initiative

Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Toga, A. W., & Beckett, L. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,493 · see citing works

Parkinson disease-associated cognitive impairment

Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C. G., Chaudhuri, К. R., & Weintraub, D. A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,441 · see citing works

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · see citing works

Price of Adaptation—Allostatic Load and Its Health Consequences: MacArthur Studies of Successful Aging

Seeman, T. E. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440400111013 · Cited by 1,368 · see citing works

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · see citing works

Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment: A Pilot Clinical Trial

Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253 · see citing works

Rivastigmine for Dementia Associated with Parkinson's Disease

Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., Deyn, P. P. D., Durif, F., Kulisevsky, J., van Laar, T., Lees, A. J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,219 · see citing works

Donepezil for dementia due to Alzheimer’s disease.

Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200 · see citing works

Memantine for dementia

McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155 · see citing works

Alzheimer’s disease

Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152 · see citing works

Systemic inflammation and disease progression in Alzheimer disease

Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139 · see citing works

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · see citing works

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · see citing works

A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia

Mathuranath, P. S., Nestor, P. J., Berrios, G. E., Rakowicz, W., & Hodges, J. R. (2000) · Neurology · doi:10.1212/01.wnl.0000434309.85312.19 · Cited by 1,029 · see citing works

Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease

Mulnard, R. A., Cotman, C. W., Kawas, C. H., van Dyck, C. H., Sano, M. C., Doody, R. S., Koss, E., Pfeiffer, E., Jin, S., Gamst, A., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1007 · Cited by 984 · see citing works

A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia

Le Bars, P. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550160047037 · Cited by 966 · see citing works

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw

Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943 · see citing works

Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy

Olazarán, J., Reisberg, B., Clare, L., Cruz, I., Peña-Casanova, J., del Ser, T., Woods, B., Beck, C., Auer, S., Lai, C., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000316119 · Cited by 937 · see citing works

A 5-month, randomized, placebo-controlled trial of galantamine in AD

Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P. R., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 915 · see citing works

Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia

Spector, A. E., Thorgrimsen, L., Woods, B. T., Royan, L., Davies, S., Butterworth, M., & Orrell, M. W. (2003) · The British Journal of Psychiatry · doi:10.1192/bjp.183.3.248 · Cited by 880 · see citing works

Untitled work

Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870 · see citing works

Social relationships, social support, and patterns of cognitive aging in healthy, high-functioning older adults: MacArthur Studies of Successful Aging.

Seeman, T. E., Lusignolo, T. M., Albert, M., & Berkman, L. (2001) · Health Psychology · doi:10.1037/0278-6133.20.4.243 · Cited by 855 · see citing works

Cognitive stimulation to improve cognitive functioning in people with dementia

Woods, B., Aguirre, E., Spector, A. E., & Orrell, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005562.pub2 · Cited by 855 · see citing works

A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease

Laxton, A. W., Tang‐Wai, D. F., McAndrews, M. P., Zumsteg, D., Wennberg, R. A., Keren, R., Wherrett, J. R., Naglie, G., Hamani, C., Smith, G. S., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22089 · Cited by 808 · see citing works

Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease

Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777 · see citing works

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750 · see citing works

Donepezil Improves Cognition and Global Function in Alzheimer Disease A 15-Week, Double-blind, Placebo-Controlled Study

Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 770 · see citing works

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771 · see citing works

Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial

Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · see citing works

Alzheimer's disease drug development pipeline: 2019

Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762 · see citing works

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752 · see citing works

Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models

Webster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A., & Van Eldik, L. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00088 · Cited by 755 · see citing works

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · see citing works

The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics

Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742 · see citing works

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

Turner, R. S., Thomas, R. G., Craft, S., van Dyck, C. H., Mintzer, J. E., Reynolds, B., Brewer, J. B., Rissman, R. A., Raman, R., Aisen, P. S. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002035 · Cited by 752 · see citing works

Amyloid Deposition, Hypometabolism, and Longitudinal Cognitive Decline

Landau, S. M., Mintun, M., Joshi, A. D., Koeppe, R., Petersen, R. C., Aisen, P., Weiner, M., & Jagust, W. J. (2012) · Annals of Neurology · doi:10.1002/ana.23650 · Cited by 723 · see citing works

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD

Winblad, B. G., Engedal, K., Soininen, H. S., Verhey, F. R. J., Waldemar, G., Wimo, A. B., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P., et al. (2001) · Neurology · doi:10.1212/wnl.57.3.489 · Cited by 721 · see citing works

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725 · see citing works

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse

Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 701 · see citing works

Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease

Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685 · see citing works

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701 · see citing works

Cognitive dysfunction in HIV patients despite long-standing suppression of viremia

Simioni, S., Cavassini, M. L., Annoni, J., Abraham, A. R., Bourquin, I., Schiffer, V., Calmy, A., Chave, J., Giacobini, E., Hirschel, B. J., et al. (2010) · AIDS · doi:10.1097/qad.0b013e3283354a7b · Cited by 701 · see citing works

Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease

Zhang, D., & Shen, D. G. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.09.069 · Cited by 679 · see citing works

Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment

DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686 · see citing works

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease

Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686 · see citing works

Overview of depression and psychosis in Alzheimer's disease

Wragg, R. E., & Jeste, D. V. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.5.577 · Cited by 683 · see citing works

Clinical trials and late‐stage drug development for <scp>A</scp>lzheimer's disease: an appraisal from 1984 to 2014

Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651 · see citing works

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease&lt;subtitle&gt;A Randomized Controlled Trial&lt;/subtitle&gt;

Green, R. C. (2009) · JAMA · doi:10.1001/jama.2009.1866 · Cited by 643 · see citing works

Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology

Smith, S. C., Lamping, D. L., Banerjee, S., Harwood, R., Foley, B., Smith, P. B., Cook, J., Murray, J., Prince, M. J., Levin, E., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9100 · Cited by 651 · see citing works

Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease: The TEAM-AD VA Cooperative Randomized Trial

Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628 · see citing works

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial

Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 623 · see citing works

A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease

Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271801 · Cited by 626 · see citing works

Comparing predictors of conversion and decline in mild cognitive impairment

Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616 · see citing works

Ginkgo biloba for cognitive impairment and dementia

Birks, J., & Evans, J. G. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003120.pub3 · Cited by 608 · see citing works

Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015

Mehta, D. G., Jackson, R., Paul, G., Shi, J., & Sabbagh, M. N. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323868 · Cited by 608 · see citing works

Assessing the Impact of Neuropsychiatric Symptoms in Alzheimer's Disease: The Neuropsychiatric Inventory Caregiver Distress Scale

Kaufer, D., Cummings, J. L., Christine, D., Bray, T., Castellon, S., Masterman, D. L., MacMillan, A., Ketchel, P., & DeKosky, S. T. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb02542.x · Cited by 607 · see citing works

Galanthamine from snowdrop?the development of a modern drug against Alzheimer?s disease from local Caucasian knowledge

Heinrich, M., & Teoh, H. L. (2004) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.02.012 · Cited by 587 · see citing works

The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1

Burns, A. S., Rossor, M. N., Hecker, J. R., Gauthier, S. G., Petit, H., Möller, H. ‐., Rogers, S. L., & Friedhoff, L. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017126 · Cited by 585 · see citing works

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568 · see citing works

Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial

(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561 · see citing works

High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease

Aisen, P. S. S. (2008) · JAMA · doi:10.1001/jama.300.15.1774 · Cited by 557 · see citing works

On the path to 2025: understanding the Alzheimer’s disease continuum

Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L., Jones, R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., et al. (2017) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-017-0283-5 · Cited by 556 · see citing works

Estrogen for Alzheimer’s disease in women

Henderson, V. W., Paganini‐Hill, A., Miller, B. L., Elble, R. J., Reyes, P. F., Shoupe, D., McCleary, C. A., Klein, R., Hake, A. M., & Farlow, M. R. (2000) · Neurology · doi:10.1212/wnl.54.2.295 · Cited by 548 · see citing works

Predictors of cognitive change in older persons: MacArthur studies of successful aging.

Albert, M., Jones, K. J., Savage, C. R., Berkman, L. F., Seeman, T. E., Blazer, D. G., & Rowe, J. W. (1995) · Psychology and Aging · doi:10.1037//0882-7974.10.4.578 · Cited by 543 · see citing works

Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database

Nestor, S. M., Rupsingh, R., Borrie, M., Smith, M., Accomazzi, V., Wells, J. L., Fogarty, J., Bartha, R., & Initiative, T. A. D. N. (2008) · Brain · doi:10.1093/brain/awn146 · Cited by 543 · see citing works

Interleukin-6 and risk of cognitive decline: MacArthur Studies of Successful Aging

Weaver, J. D., Huang, M.-H., Albert, M., Harris, T., Rowe, J. W., & Seeman, T. E. (2002) · Neurology · doi:10.1212/wnl.59.3.371 · Cited by 536 · see citing works

Rivastigmine for Alzheimer’s disease.

Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534 · see citing works

Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies

Alexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I., & Reiman, E. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.738 · Cited by 532 · see citing works

Conversion of amyloid positive and negative MCI to AD over 3 years

Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F., Någren, K., Bullock, R. M., Walker, Z., Kennedy, A. M., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b23564 · Cited by 522 · see citing works

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis

Hansen, R. A., Webb, A. P., Moore, C. G., Gartlehner, G., Jonas, D. E., & Morgan, L. C. (2020) · PubMed Central · doi:10.17615/ae8c-2p76 · Cited by 523 · see citing works

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

Palmqvist, S., Tideman, P., Cullen, N., Zetterberg, H., Blennow, K., Initiative, T. A. D. N., Dage, J. L., Stomrud, E., Janelidze, S., Mattsson-Carlgren, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01348-z · Cited by 524 · see citing works

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522 · see citing works

Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study

Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., Hotton, G., Cutler, D., Fox, N., Kennedy, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000244749.20056.d4 · Cited by 518 · see citing works

Donepezil for dementia due to Alzheimer's disease

Birks, J., & Harvey, R. J. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190 · Cited by 515 · see citing works

Montreal Cognitive Assessment

Freitas, S., Simões, M. R., Alves, L., & Santana, I. J. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3182420bfe · Cited by 511 · see citing works

Effects of β-hydroxybutyrate on cognition in memory-impaired adults

Reger, M. A., Henderson, S. T., Hale, C. M., Cholerton, B., Baker, L. D., Watson, G. S., Hyde, K., Chapman, D., & Craft, S. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00087-3 · Cited by 510 · see citing works

High, usual and impaired functioning in community-dwelling older men and women: Findings from the MacArthur Foundation Research Network on successful aging

Berkman, L. F., Seeman, T. E., Albert, M., Blazer, D. G., Kahn, R. L., Mohs, R. C., Finch, C. E., Schneider, E. L., Cotman, C. W., McClearn, G. E., et al. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90112-e · Cited by 499 · see citing works

Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease

Davis, K. L. (1999) · JAMA · doi:10.1001/jama.281.15.1401 · Cited by 492 · see citing works

Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients

Ahn, H.-J., Chin, J., Park, A., Lee, B. H., Suh, M. K., Seo, S. W., & Na, D. L. (2010) · Journal of Korean Medical Science · doi:10.3346/jkms.2010.25.7.1071 · Cited by 487 · see citing works

Allostatic load as a predictor of functional decline

Karlamangla, A. S., Singer, B. H., McEwen, B. S., Rowe, J. W., & Seeman, T. E. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00399-2 · Cited by 483 · see citing works

The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease

Voevodskaya, O., Simmons, A., Nordenskjöld, R., Kullberg, J., Ahlström, H., Lind, L., Wahlund, L., Larsson, E., Westman, E., & Initiative, A. D. N. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00264 · Cited by 473 · see citing works

A randomized controlled trial of prednisone in Alzheimer’s disease

Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464 · see citing works

Periodontitis and Cognitive Decline in Alzheimer’s Disease

Ide, M., Harris, M., Stevens, A., Sussams, R., Hopkins, V., Culliford, D., Fuller, J., Ibbett, P., Raybould, R., Thomas, R., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151081 · Cited by 461 · see citing works

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

Doody, R. S., Si, G., Sano, M. C., Thomas, R. G., Aisen, P. S. S., Бачурин, С. О., Seely, L., & Hung, D. S.-Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460 · see citing works

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438 · see citing works

Development of a novel convenient Alzheimer's disease assessment scale, the ABC Dementia Scale, using item response theory

Umeda‐Kameyama, Y., Mori, T., Wada‐Isoe, K., Kikuchi, T., Kojima, S., Kagimura, T., Ueki, A., Watabe, T., Kudoh, C., Akishita, M., et al. (2018) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13552 · Cited by 34 · see citing works

The Evaluation of Behavioral Disturbances in Alzheimer's Disease: The Utility of Three Rating Scales

Mack, J. L., & Patterson, M. B. (1994) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879400700206 · Cited by 26 · see citing works

A New Scale for the Assessment of Functional Status in Alzheimer's Disease and Related Disorders

Loewenstein, D., Amigo, E. M., Duara, R., Guterman, A., Hurwitz, D., Berkowitz, N., Wilkie, F. L., Weinberg, G. B., Black, B., Gittelman, B., et al. (1989) · Journal of Gerontology · doi:10.1093/geronj/44.4.p114 · Cited by 356 · see citing works

The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease

Tariot, P. N., Mack, J. L., Patterson, M. B., Edland, S. D., Weiner, M., Fillenbaum, G. G., Blazina, L., Teri, L. L., Rubin, E. H., & Mortimer, J. A. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.9.1349 · Cited by 425 · see citing works

The Evaluation of Behavioral Disturbances in Disease: The Utility of Three Alzheimer’s

Scales, R., Mack, J. L., Marian, P., & Patterson, B. (2016)